Q1 2022 Results

Company overview Financial review 2022 priorities Appendix References Novartis appoints Aharon (Ronny) Gal, Ph.D. as Chief Strategy & Growth Officer 27 Investor Relations | Q1 2022 Results Effective no later than August 1, 2022 Leads the newly created Strategy & Growth function that combines corporate strategy, R&D portfolio strategy and business development ■ Reports to CEO and joins Executive Committee of Novartis ■ Brings over 20 years of life-sciences industry experience including financial research and analytics, management consulting and business development NOVARTIS | Reimagining Medicine

View entire presentation